Lobe Sciences (OTCQB:LOBEF) has announced a significant stride in its European market expansion, confirming the validation of its European Unitary Patent EP4117446. This patent grants coverage across 17 EU member states, underpinning the company’s proprietary DHA-based composition specifically formulated to address Sickle Cell Disease (SCD).
The validated patent specifically protects Altemia®, a physician-supervised medical food designed for SCD patients. This innovative formulation tackles long-chain fatty acid deficiencies by combining DHA with natural emulsifiers. The key benefit lies in its ability to enhance bioavailability while crucially restoring the integrity of red blood cells.
This validation is more than just a legal formality; it represents a substantial boost to Lobe’s intellectual property fortifications in crucial European territories, decidedly strengthening the company’s commercialization roadmap for Altemia®.
Lobe Sciences (OTCQB:LOBEF) ha annunciato un passo significativo nella sua espansione nel mercato europeo, confermando la convalida del suo Brevetto Unitario Europeo EP4117446. Questo brevetto offre copertura in 17 Stati membri dell’UE, sostenendo la composizione proprietaria dell’azienda a base di DHA specificamente formulata per affrontare la Malattia delle Cellule Falciformi (SCD).
Il brevetto convalidato protegge specificamente Altemia®, un alimento medico supervisionato da medici, progettato per pazienti con SCD. Questa innovativa formulazione affronta le carenze di acidi grassi a catena lunga combinando DHA con emulsionanti naturali. Il vantaggio chiave risiede nella sua capacità di migliorare la biodisponibilità e, soprattutto, di ripristinare l’integrità dei globuli rossi.
Questa convalida è più di una mera formalità legale; rappresenta un notevole impulso alle fortificazioni della proprietà intellettuale di Lobe in territori europei cruciali, rafforzando decisamente la roadmap di commercializzazione dell’azienda per Altemia®.
Lobe Sciences (OTCQB:LOBEF) ha anunciado un avance significativo en su expansión en el mercado europeo, confirmando la validación de su Patente Unitaria Europea EP4117446. Esta patente otorga cobertura en 17 Estados miembros de la UE, respaldando la composición patentada de la compañía basada en DHA, formulada específicamente para abordar la Enfermedad de Células Falciformes (SCD).
La patente validada protege específicamente Altemia®, un alimento médico supervisado por médicos diseñado para pacientes con SCD. Esta innovadora formulación aborda las deficiencias de ácidos grasos de cadena larga al combinar DHA con emulsionantes naturales. El beneficio clave radica en su capacidad para mejorar la biodisponibilidad y, crucialmente, restaurar la integridad de los glóbulos rojos.
Esta validación es más que una simple formalidad legal; representa un impulso sustancial para las fortificaciones de propiedad intelectual de Lobe en territorios europeos cruciales, fortaleciendo decididamente la hoja de ruta de comercialización de la compañía para Altemia®.
Lobe Sciences (OTCQB:LOBEF)는 유럽 시장 확장에 있어 중요한 발걸음을 내디뎠다고 발표하며, 자사의 유럽 단일 특허 EP4117446이 유효함을 확인했습니다. 이 특허는 낫적혈구병(SCD)을 겨냥하여 특별히 개발된 DHA 기반 조성물에 대해 17개 EU 회원국 전역에서 효력을 발휘합니다.
유효성이 확인된 특허는 SCD 환자를 위해 개발된 의사 감독하의 의료용 식품인 Altemia®를 특정적으로 보호합니다. 이 혁신적인 제형은 DHA와 천연 유화제를 결합하여 장쇄 지방산 결핍을 해결합니다. 핵심 이점은 생체 이용률을 개선하고 적혈구의 완전성을 복구하는 능력에 있습니다.
이번 유효성 확인은 단순한 법적 절차를 넘어, 유럽 주요 시장에서의 Lobe의 지적 재산권 강화에 대한 상당한 추진력을 나타내며, Altemia®의 상업화 로드맵을 확고히 합니다.
Lobe Sciences (OTCQB:LOBEF) a annoncé une étape significative dans son expansion sur le marché européen, confirmant la validation de son Brevet Unitaire Européen EP4117446. Ce brevet accorde une protection dans 17 États membres de l’UE, soutenant la composition exclusive de la société à base de DHA, spécifiquement formulée pour cibler la drépanocytose (SCD).
Le brevet validé protège spécifiquement Altemia®, un aliment médical supervisé par des médecins et conçu pour les patients atteints de SCD. Cette formulation innovante s’attaque aux carences en acides gras à longue chaîne en combinant le DHA avec des émulsifiants naturels. L’avantage clé réside dans sa capacité à améliorer la biodisponibilité tout en restaurant de manière cruciale l’intégrité des globules rouges.
Cette validation est plus qu’une simple formalité juridique ; elle représente une impulsion substantielle pour les fortifications de la propriété intellectuelle de Lobe dans des territoires européens cruciaux, renforçant ainsi résolument la feuille de route de commercialisation de la société pour Altemia®.
Lobe Sciences (OTCQB:LOBEF) hat einen bedeutenden Schritt in seiner Expansion auf dem europäischen Markt angekündigt und die Validierung seines europäischen Einheitspatents EP4117446 bestätigt. Dieses Patent gewährt Schutz in 17 EU-Mitgliedstaaten und untermauert die proprietäre DHA-basierte Zusammensetzung des Unternehmens, die speziell zur Behandlung der Sichelzellenkrankheit (SCD) entwickelt wurde.
Das validierte Patent schützt insbesondere Altemia®, ein medizinisch überwachtes Nahrungsmittel für SCD-Patienten. Diese innovative Formulierung bekämpft Langkettige Fettsäuredefizite durch die Kombination von DHA mit natürlichen Emulgatoren. Der Hauptvorteil liegt in seiner Fähigkeit, die Bioverfügbarkeit zu verbessern und gleichzeitig entscheidend die Integrität der roten Blutkörperchen wiederherzustellen.
Diese Validierung ist mehr als nur eine formale Formalität; sie stellt einen wesentlichen Schub für Lobes geistiges Eigentum in entscheidenden europäischen Gebieten dar und stärkt damit nachdrücklich die kommerzielle Roadmap des Unternehmens für Altemia®.
Positive
- Patent protection secured in 17 European Union member states
- First-in-class emulsified oral formulation for SCD treatment
- Strengthened intellectual property portfolio for European market expansion
Negative
- Romania’s patent protection delayed until September 1, 2024
07/08/2025 – 12:01 AM
-
European Unitary Patent EP4117446 Validated across 17 EU member states for Lobe Sciences’ DHA-based Sickle Cell Disease composition, bolstering commercialization efforts for Altemia®.
-
Altemia® Medical Food, the first-in-class emulsified oral formulation for SCD treatment, is now covered by the new patent.
-
The validation significantly strengthens Lobe’s intellectual property portfolio, supporting its strategic global expansion goals within key European markets.
VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / Lobe Sciences Ltd. (CSE:LOBE), (OTCQB:LOBEF), (FWB:LOBE.F), a biopharmaceutical innovator focused on addressing critical unmet needs in rare diseases, today announced a pivotal moment in its European market strategy: the official validation of its European Patent EP4117446 as a Unitary Patent by the European Patent Office.
The patent, meticulously detailed under the title “A Composition Comprising Docosahexaenoic Acid… for Sickle Cell Disease Treatment,” safeguards novel formulations that synergistically combine DHA with specialized ingredients. This strategic combination is engineered to effectively counteract fatty acid deficiencies and mitigate the cascade of related complications inherent in Sickle Cell Disease (SCD).
This newly validated Unitary Patent extends Lobe Sciences’ intellectual property protection across a robust network of 17 European Union member states. The covered territories include Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Portugal, Sweden, and Slovenia. Notably, Romania’s coverage is set to commence on September 1, 2024.
This validation serves as a significant accelerant for Lobe’s ambition to broaden the global footprint of its flagship Altemia® Medical Food. Altemia® itself is a groundbreaking, first-in-class emulsified oral formulation meticulously developed to restore the critical integrity of red blood cell membranes in patients battling SCD. The formulation’s efficacy hinges on its sophisticated blend of DHA and natural emulsifiers, which collectively enhance absorption and maximize its impact in managing long-chain fatty acid deficiencies – a central pathological hallmark of SCD.
“Securing this Unitary Patent across such a significant bloc of European markets represents a major leap forward in safeguarding and expanding the reach of our proprietary SCD treatment technology,” stated Dr. Fred D. Sancilio, CEO of Lobe Sciences. “This achievement is instrumental as we remain steadfast in our mission to bring impactful nutritional and therapeutic innovations to patients who are currently underserved and often overlooked.”
About Lobe Sciences – Lobe Sciences Ltd. is a dynamic biopharmaceutical company dedicated to pioneering therapies for conditions that lack adequate treatment options. Operating through its subsidiaries, Altemia, Inc. and Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented, lipid-based platform specifically designed to combat Sickle Cell Disease. Concurrently, the company is developing a novel oral analog of psilocin, branded as Conjugated Psilocin™, targeting debilitating neurological disorders like Chronic Cluster Headache. These initiatives are strategically aligned to address substantial unmet medical needs, promising to elevate patient outcomes across both hematologic and neuropsychiatric landscapes.
For further information:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media Relations
[email protected]
Phone: +1 (949) 505-5623
Cautionary Statement Regarding “Forward-Looking” Information
This news release contains statements that may be construed as forward-looking information under applicable Canadian securities laws. These statements, which are not historical facts, encompass future estimates, plans, objectives, timing assumptions, and expectations of performance. This includes, but is not limited to, company intentions regarding funding for clinical trials, the innovative nature of Conjugated Psilocin™, the anticipated focus, timing, and efficiency of research and development activities, the potential for the company’s products to meet unmet medical needs, the intended use of offering proceeds, development plans for Cynaptec, Lobe Sciences’ intention to provide services to Cynaptec, the potential exercise of options, and the ability to secure funding for clinical development. Forward-looking statements are typically identified by phrases such as “intends,” “anticipates,” or variations thereof, or statements that certain actions, events, or results “may,” “could,” “should,” or “would” occur.
Such statements are based on the Company’s material assumptions and analyses, as well as management’s opinions and estimates as of the date of this press release. These assumptions include, but are not limited to, the belief that the Company’s planned activities will generate shareholder value and address serious unmet medical needs, that the Company will proceed with its planned research and development, and that it will secure necessary funding. However, these forward-looking statements are subject to inherent risks, uncertainties, and other factors, both known and unknown, which could cause the Company’s actual results, activity levels, performance, or achievements to differ materially from those expressed or implied. Key risks include, but are not limited to, the possibility that the Company’s planned activities may not create shareholder value or address targeted unmet medical needs, that the Company may not achieve desired results from its current research and development, and that it may be unable to raise funds or do so within anticipated timelines.
While management has endeavored to identify key factors that could cause actual results to diverge materially from forward-looking statements, other factors may arise that could lead to outcomes that differ from expectations, estimates, or intentions. There can be no assurance that such statements will prove accurate, as actual results and future events could materially differ. Accordingly, readers should exercise caution and not place undue reliance on these forward-looking statements. Readers are advised that reliance on such information may not be appropriate for other purposes. The Company undertakes no obligation to update any forward-looking statement, forward-looking information, or financial outlook incorporated by reference herein, except as required by applicable securities laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.
SOURCE: Lobe Sciences Ltd.
View the original press release on ACCESS Newswire
Frequently Asked Questions
What is the significance of Lobe Sciences’ (LOBEF) European Unitary Patent validation?
The validation secures patent protection across 17 European Union member states for Lobe’s DHA-based composition targeting Sickle Cell Disease. This strategic move is designed to unlock broader commercialization opportunities for Altemia® throughout key European markets.
What is Altemia® and how does it address Sickle Cell Disease?
Altemia® is a pioneering, physician-supervised medical food that leverages a unique combination of DHA and natural emulsifiers. This formulation is engineered to restore red blood cell membrane integrity and effectively address the long-chain fatty acid deficiencies that are characteristic of SCD.
Which European countries are covered by Lobe Sciences’ newly validated patent?
The comprehensive patent coverage extends to 17 EU member states, including Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Portugal, Sweden, and Slovenia. Romania’s inclusion is slated to commence on September 1, 2024.
How does this patent validation impact Lobe Sciences’ business strategy?
This crucial validation significantly bolsters Lobe’s intellectual property portfolio, providing a robust foundation for its ambitious global expansion strategy. It paves the way for more effective and widespread commercialization of Altemia® across the vital European pharmaceutical landscape.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/4228.html
